hease type a plus sign (+) inside this box

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031\*
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Complete if Known

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

bstitute for form 1449A/PTO

Sheet

(use as many sheets as necessary)

of 1

Application Number 10/009,950 12/04/2001 Filing Date First Named Inventor Akira NAKAMURA 1632 Group Art Unit Examiner Name V. BERTOGLIO 31671-176197 Attorney Docket Number

		OTHER PRIOR ART NON PATENT LITERATURE DOCUMENTS	
Examiner	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
B	A1	W. Kline BOLTON et al., "Goodpasture's Epitope in Development of Experimental Autoimmune Glomerulonephritis in Rats", Kidney International, Vol. 49, (1996), pp. 327-334.	
16	A2	Mauro Abbate et al., "Experimental Goodpasture's Syndrome in Wistar- Kyoto Rats Immunized with a3 Chain of Type IV Collagen", Kidney International, Vol. 54 (1998), pp. 1550-1561.	
B	A3	Raghu KALLURI, "Goodpasture Syndrome", Kidney International, Vol. 55 (1999), pp 1120-1122.	
·			
		·	
		1	

Examiner Signature	W.	Date Considered	10/02/04	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450.

PC Docs No. 570460v1

<sup>&</sup>lt;sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.